Kestra Medical Technologies 8th Annual Wolfe Research Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon. Welcome to the Wolfe Healthcare Conference. My name is Mike Polark, medical device analyst here at Wolfe Research. Pleased in this session to be joined by Kestra Medical CEO Brian Webster, CFO Vaseem Mahboob. Brian and Vaseem, welcome. Thanks for being here.
Thanks, Mike. Brian, I'll pass it to you to set the stage, and then we can jump into some Q&A.
Maybe reflect on the last 18 Kestra's been public for about 18 months, call it a year and a half, almost two years. Just reflect on those couple years of the journey. Kestra's obviously been a much longer journey, but you're in growth mode, you're in execution mode. What stands out? What are you most proud of, and what excites you about the road ahead?
Yeah. Well, I appreciate the question, and Mike, thanks for having us here today. I think it's been quite a journey over the last 18 months. We went from sort of the shock treatment of trying to take a private company public and all the things that have to happen to do that effectively, all the process development, people development, all those things. We're kind of on, I think, mostly on the other side of that now, so those are becoming more a part of our normal cadence and our normal day. I think there's a couple things that we're really excited about. One, you've seen the steady execution coming from the company, and I think we really like to have a high say-do ratio.
When we say we're going to do something, we like to really be good at following through and doing that. I think so far we've been doing that, and that's because we've got just an amazing team. We're excited about the market. The market is growing. I'm sure we'll talk about that, but the more we get into the category and we understand the different patient needs and clinical needs, the more problems that we think we can solve. Ultimately, when you're a company that has a really strong engineering and clinical capability, that's what you're looking for. You're looking for problems to solve. I think we, across the company, are just really excited about solving more issues in the future and adding to our platforms and continuing to just drive what's a really exciting growth engine into the future.
Good setting of the stage. I will ask about the WCD market. I think we see Kestra's numbers, the growth rates are high. It's very clear you're taking share, but the incumbent here has a very large business, and they've talked more constructively about their WCD performance. I view this glass half full. It's good to see that. It validates the market opportunity, which is described as very large despite the incumbent having product in the market for two decades. I think it's very healthy. My question to you is, why? What are the one, two, or three things that you think are creating space for you to have great success and also helping, and that might also be helping their performance?
Well, I think first and foremost, you have to accept the fact that we came into the market and we solved a problem that was there. The reason that market, which I consider the kind of the classical WCD market to be the post-MI patient, the usually guy who's been revascularized. He's probably going to be a candidate for an implantable device in 45 or 90 days. The issue that we solved was wearability, was the false alarm issue, was all the gender specificity issue. All the things that were preventing that market from growing, we solved, so we're seeing that unfold. That's one reason why you're seeing the strong growth.
I think anytime you get a second company coming into a monopoly market, I think in med tech we've seen lots of cases like that where having somebody echoing the messaging around the need for that category always drives market growth, so that's pretty well established. Both companies, Kestra, we published about a year ago, we published our ACE-PAS, which is our FDA post-approval study data, 21,000 patients. Among the things that that study demonstrated was that the risk level for these patients was higher than most of the clinicians really appreciated, and in particular with the heart failure patients. We've been out there really beating the drums about that issue, and consequently, we're seeing more prescribers who are prescribing that maybe weren't prescribing to the broader range of their patients than they have before.
ZOLL also published a large study, a German registry study, that essentially showed the same thing. They are out selling the same message. When you have two companies with 40,000 patients worth of data echoing the same messaging around that category, that is what leads to market growth. On top of all those things, we are doing some really exciting stuff when it comes to medical education. We have had some really highly successful APP education programs recently in different locations around the country. I think it is a combination of all those things. By our math, with the ZOLL recent earnings release and our own, we see the market the last 12 months, it has grown at 14%. That is pretty healthy for a billion-dollar-plus category. We are pretty excited about that.
Do you have hard evidence to suggest heart failure is growing faster than post-MI, or do you believe both slices of hamburger?
It is definitely growing faster than post-MI. The population itself of patients who are experiencing heart failure is definitely growing faster, but we see in our own data that that patient population is growing faster than the post-MI patients. The nice thing for us, of course, in our model, in the rental model, is those heart failure patients are also longer wear patients, and longer wear has better economics attached to that. We are helping to solve a problem for that patient population, but that also is attractive economically.
On the prescriber comment, so existing prescribers prescribing more broadly, what about in the last year as market growth has perked up? What can you discern about new prescribers engaging with this product? Is it mostly the same store growth, or are there new stores, new prescribers that is meaningful?
I think our view is it's probably 75% of it's same store growth, and a quarter of it is new prescribers. There's definitely new prescribers that are seeing this. Especially what we're seeing is in some of our fellows programs where we're trying to really do some education with fellows, they really are attracted to newer technologies, updated modern technologies. They look at our kind of a device, and they look at it and say, "Hey, there's more utility to this than just a standard shock box," like they've been used to with a competitive device. They're looking at it as another tool that they can use to help manage these patients. That's been one of the drivers in some of those prescriber populations.
I'll ask on the guidelines. Heart failure in the U.S. still doesn't have guideline support, but between SCD-PROTECT and ACE-PAS, there's a substantial amount of new data, and I believe mostly that data is focused on this heart failure patient population. If I have it correct, the guidelines for WCD were last adjusted in 2017, 10 years ago.
What needs to happen next for some credit in the guidelines? Is there an identifiable pathway review timeline? Is this enough data, you think, to sway the guidelines, these two large studies, or is something more needed?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
